CITI/PUT/MODERNA/60/0.1/16.01.25 | Market Closed - Börse Stuttgart 20:50:06 27/06/2024 BST | ||
| 0.07 EUR | -12.50% |
|
| Current month | +48.94% | ||
| 1 month | +268.42% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 27/06/24 | 0.07 | -12.50% |
| 26/06/24 | 0.08 | +70.21% |
| 25/06/24 | 0.047 | +2.17% |
| 24/06/24 | 0.046 | -16.36% |
| 21/06/24 | 0.055 | +14.58% |
Delayed Quote Börse Stuttgart
Last update June 27, 2024 at 08:50 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | MODERNA, INC. |
| Issuer | 
Citi
|
| WKN | KJ0BMA |
| ISIN | DE000KJ0BMA9 |
| Date issued | 26/09/2023 |
| Strike | 60 $ |
| Maturity | 16/01/2025 (203 Days) |
| Parity | 10 : 1 |
| Emission price | 0.47 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.09 € |
|---|---|
| Lowest since issue | 0.01 € |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
121.2
USD
Average target price
145.9
USD
Spread / Average Target
+20.36%
- Stock Market
- Warrants
- Warrant
